“…In current clinical practice, peri‐ and post‐operative chemoprophylaxis (enoxaparin, heparin [UFH], or aspirin) has become the standard of care after major H&N surgery (C. J. Pannucci et al, 2011; Christopher J. Pannucci et al, 2021; Venkatesh et al, 2020). However, breakthrough VTE can occur even in the presence of chemoprophylaxis (Ong et al, 2017; Christopher J. Pannucci et al, 2021; Tipirneni et al, 2021; Venkatesh et al, 2020; Saadoun et al., 2022). In fact, VTE risk has been reported between 1.4% to 6% when patients received antithrombotic agents perioperatively (Bahl et al, 2014; Chen et al, 2008; Moreano et al, 1998; Ricci et al, 2016; Thai et al, 2013; Venkatesh et al, 2020).…”